semaj83/ctmatch_classification huggingface dataset:
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-4.0,  Turner's Syndrome Young girls with turner syndrome proved by karyotype Growth hormone secretion confirmed with ornithin stimulation test Normal glucidic metabolism confirmed by assessment of HbA1c None associated severe pathology which could have impact on growth (i.e. renal insufficiency, decompensated heart failure) No previous or associated treatment with anabolic or sexual steroids Known parental height  Severe associated pathology with impact on growth Concomitant treatment with impact on growth Previous or associated treatment with anabolic steroids Associated growth hormone deficiency
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-50.0,  Developmental Disabilities Developmental disorders  Mental retardation
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-18.0,  Idiopathic Short Stature Males: Ages: 12 less than 18 years Bone age less than 14 ½ years at study initiation Presence of puberty Idiopathic short stature will be defined as a short child equal or less than -2SD for height, with normal GH responses to stimuli (> or = 5ng/ml to at least 2 secretagogues) or a normal IGF-I and BP-3, normal body proportions and no other identifiable growth pathology Accurate growth data for at least 6 months at baseline is available  Chronic illnesses Chronic use of glucocorticosteroids Previous use of hormonal treatment with AIs, sex steroids or GH in the preceding 6 months Birth weight small for gestational age (SGA)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-24.0,  Transient Tachypnea of the Newborn gestational age ≥ 35 weeks diagnosis of TTN, defined as respiratory rate >60, presence of subcostal and /or intercostal retractions, nasal flaring, grunting, oxygen saturations 70-93% on room air, and radiological evidence of perihilar streaking and patchy infiltrates admission to the NICU at Mount Sinai hospital within first 24 hours of life  gestational age < 35 weeks history of thick meconium stained fluid and/or diagnosis of meconium aspiration syndrome diagnosis of major congenital pulmonary or cardiac anomalies initial CXR demonstrating air leak respiratory distress first occurring after 24 hours of life presumptive diagnosis of RDS as indicated by the need for FiO2 > 40%, severe retractions and grunting with poor air entry, and diffuse alveolar consolidation on chest radiograph
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Eisenmenger's Syndrome patients with Eisenmenger's syndrome diagnosed by right side cardiac catheterization
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-1.0,  Gastritis of Newborn Other Vomiting of Newborn Meconium in Amniotic Fluid Gestation > 34 weeks Meconium staining of amniotic fluid Vigorous babies  Major Congenital malformation Non vigorous babies Refusal of consent
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Marfan Syndrome Turner Syndrome Ehlers-Danlos Syndrome Loeys-Dietz Syndrome FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 Genetic Mutation Bicuspid Aortic Valve Without Known Family History Bicuspid Aortic Valve With Family History Bicuspid Aortic Valve With Coarctation Familial Thoracic Aortic Aneurysm and Dissections Shprintzen-Goldberg Syndrome Other Aneur/Diss of Thoracic Aorta Not Due to Trauma, <50yo Other Congenital Heart Disease Eligible subjects must have one of the conditions listed below and be enrolled in-person at one of the participating clinical centers.Contact the study coordinator at the location nearest you for more information about participation Marfan syndrome Turner syndrome Ehlers-Danlos syndrome Loeys-Dietz syndrome FBN1, TGFBR1, TGFBR2, ACTA2 or MYH11 genetic mutation Bicuspid aortic valve without known family history Bicuspid aortic valve with family history Bicuspid aortic valve with coarctation Familial Thoracic Aortic Aneurysm and DissectionsYes  Inability of the patient, parent or guardian to give consent Unwillingness to provide a blood or buccal specimen
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 7.0-16.0,  Pain Male and female patients, 7 to 16 years of age, inclusive, with malignant and/or nonmalignant moderate to severe pain requiring or anticipated to require continuous, around-the-clock, opioid treatment for at least 2 weeks (based on the investigator's judgment) Patients must have written informed consent provided by the parent or legal guardian and assent provided by the patient, when appropriate Patients on incoming opioids must be taking ≤ 80 mg/day morphine or equivalent if aged 12 to 16 years or ≤ 40 mg/day morphine or equivalent if aged 7 to 11 years prior to the screening visit Patients and patient's parent/caregiver must be compliant with the protocol, ie, must be able to perform study assessments and understand and complete the age-appropriate scale to rate pain intensity. Patients must not have a cognitive developmental delay or any other condition that would preclude them from completing the age-appropriate pain scale  Patients who are allergic to buprenorphine or have a history of allergies to other opioids (this criterion does not patients who have experienced common opioid side effects [eg, nausea, constipation]) or who have allergies or other contraindications to transdermal delivery systems or patch adhesives Patients with a dermatological disorder, including burn and skin graft sites, at any relevant patch application site that would preclude proper placement and/or rotation of BTDS patches Patients with evidence of impaired renal function Patients with hepatic impairment Patients with history of seizures Patients with intracranial pressure Patients who have a history of sleep apnea within the past year Patients who require mechanical ventilation during study treatment period, are cyanotic, or who have unstable respiratory disease Patients with clinically significant structural heart disease or a pacemaker Patients with clinically unstable cardiac disease
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-80.0,  Malignant Neoplasm of Thyroid Stage I Malignant Neoplasm of Thyroid Stage II papillary or follicular thyroid cancer stage 1 or 2 according to TNM system version 6 surgery and radioiodine treatment levothyroxine suppression treatment  cardiopulmonary failure liver failure renal failure pregnancy drugs (colestyramin, sucralfate, phenobarbital, phenytoin, carbamazepin, rifampin, amiodarone, chloroquin, androgens, sertraline, frusemide, heparin)
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Growth Hormone Deficiency have a height less than two standard deviations (SD) below the median height for individuals of the same age or height, a growth velocity (GV) ≤4 cm/yr, a GH peak concentration <7 ng/ml in two different provocative tests, a bone age (BA; ≤9 years in girls and ≤10 years in boys) at least 2 years less than his/her chronological age (CA) be in preadolescence (Tanner stage 1) and have a CA >3 years have a height value recorded 3 months before the start of GH treatment to calculate pre-treatment GV receive no prior GH treatment sign informed consent  patients with severe cardiopulmonary patients with hematological diseases a current or past history of malignant tumors immunodeficiency diseases mental diseases patients positive for hepatitis B e-antibody (HBeAb) hepatitis B surface antigen (HBsAg) hepatitis B e antigen (HBeAg) patients with other growth disorders, such as Turner syndrome constitutional delay of growth and puberty, and Laron syndrome
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Sepsis Syndromes Systemic inflammatory response syndrome with a proven or suspected infectious etiology years and over Relatives willing to give consent Admitted to intensive care and likely to remain ventilated for > 48 hours  Patients with septic shock unresponsive to maximal treatment or who are moribund or have an expected mortality within 48 hours Head injuries Burn injury Multiple lower limb fractures
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Growth Hormone Deficiency therapeutic need according to SPC written informed consent  contraindications according to SPC
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.917-1.083,  Turner Syndrome Diagnosis of Turner syndrome Less than the 50th percentile for length for the general female population  Prior Growth Hormone (GH) therapy Diabetes Allergy to metacresol (a preservative in the GH liquid that is injected) Contraindications for Magnetic Resonance Imaging (MRI) (such as metal in the body) Part of a Y chromosome in child's karyotype Parent/guardian is not willing for child to be randomized to be in the treatment group (receives Growth Hormone injections for one year) or the control group (receives no Growth Hormone during the study) Parent/guardian is not willing for child to have some of her developmental testing digitally recorded for scoring
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 1.0-25.0,  Turner Syndrome Ovarian Insufficiency girls aged from 1 to 25 years included with Turner syndrome or mosaic patients aged more than 18 will only have ovarian insufficiency dated less than 5 years without any severe disease, particularly of cardiovascular type whose agreement to participate to the study has been signed by the parents whose agreement to participate to the study has been signed by majority age patient  girls aged less than one year and over 25 years old if any surgery would be contra-indicated ovary alone presence Well-known infection by HIV, and/or HBV, and/or HCV and/or syphilis TPHA VDRL No social coverage affiliate
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-18.0,  Idiopathic Growth Hormone Deficiency Turner Syndrome Pre-established diagnosis of IGHD or TS based on classical with at least 1 year of r-hGH therapy and with Tanner stage 1 at treatment start Retrospective availability of a complete set of clinical, auxological and biological parameters necessary for building the predictive model Other protocol defined could apply  Acquired growth hormone deficiency (GHD) Any drug or disease that could affect growth during the first year of r-hGH treatment Other protocol defined could apply
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 7.0-14.0,  Polycystic Ovary Syndrome Hyperandrogenism Normal Puberty Female volunteers in early to mid-puberty (i.e., late Tanner I [estradiol level > 20 pg/mL], Tanner II, or Tanner III) Premenarcheal  Pregnancy Inability to comprehend what will be done during the study or why it will be done Hemoglobin less than 12 g/dl and hematocrit less than 36% Persistently abnormal sodium, potassium, or bicarbonate (i.e., confirmed on repeat) Persistently elevated creatinine, hepatic transaminases, or alkaline phosphatase (i.e., confirmed on repeat) Total bilirubin > 1.5 times upper limit of normal (i.e., confirmed on repeat) Significant history of cardiac or pulmonary dysfunction (e.g., known or suspected congestive heart failure; asthma requiring intermittent systemic corticosteroids; etc.) Untreated hypo or hyperthyroidism, reflected by persistently abnormal thyroid-stimulating hormone (TSH) values Total testosterone > 200 ng/dl
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 8.0-14.0,  Hyperandrogenemia Polycystic Ovary Syndrome Girls ages 8 to 14 Tanner 1-3 pubertal stage Pre-menarchal Normal screening labs  Abnormal screening labs Congenital adrenal hyperplasia Hyperandrogenism (e.g., hirsutism, elevated free testosterone level) Hemoglobin <12 mg/dL or hematocrit < 36% (Subjects will be offered the opportunity to take iron supplementation for 60 days if their hematocrit is slightly low (33-36%) (suggestive of iron deficiency anemia) and will then return for retesting of their hemoglobin/hematocrit.) Weight < 31 kg History of peanut allergy, deep venous thrombosis, breast cancer, endometrial cancer, or cervical cancer On hormonal medications (including oral contraceptive pills) or on medications known to affect the reproductive axis within 3 months of the study Pregnant or breast feeding Participation in a research study within the past 30 days that involved taking a study drug Participation in a research study that involved taking up to or greater than 473 ml's of blood within the past 60 days
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Global Developmental Delay Cerebral Palsy Mental Retardation Pervasive Developmental Disorders GDD diagnosis in two axis' at least BSID test in its second or third version  If not all of the data is available for all of the assessments
Patient description: A 12 year old girl came to the clinic with her mother, complaining of short stature, delayed in puberty and developmental delay. Her karyotype study revealed 45X and confirmed the diagnosis of Turner syndrome. She is treating with GH since 6 months ago without estrogen therapy to avoid menarche and reach the ideal height. She is an obese, mentally retarded girl in the physical exam. Her breast bulb were in stage 1 with no course hair in the pubic or axillary. Her TSH was 3 and FBS was 75 in the latest lab study.

Clinical trial eligibility criteria: eligible ages (years): 12.0-17.0,  Delayed Puberty Kallmann Syndrome Hypogonadotropic Hypogonadism GnRH Deficiency Adolescent Boys ages 13.5-17 years testicular volume <4 mL OR 4-8 ml with no change in the past 6 months by Prader orchidometer first morning (before 9AM) LH <2 mIU/mL and testosterone <50 ng/dL Adolescent Girls ages 12-17 years Tanner stage I OR II breast development with no change in the past 6 months first morning (before 9AM) LH <2 mIU/mL and estradiol <20 pg/ml All Subjects bone age less than chronological age weight ≥ 28 kg body mass index >10th percentile and <+3 SDS for bone age  All Subjects history or presence of underlying condition that could cause delayed puberty (chronic illness, weight loss, abnormal cranial magnetic resonance imaging (MRI)) history of an allergic drug reaction